PCV133 THE COST-EFFECTIVENESS OF GENOTYPING CYP2C19 TO GUIDE ANTIPLATELET THERAPY SELECTION  by Reese, ES et al.
Abstracts A175
ics. SAS version 9.2 was used for analyses of data. Descriptive statistics were obtained 
by using survey frequency procedures that accounted for survey design and weighting. 
Weighted analyses were performed using survey logistic procedure controlling for 
interactions amongst the independent variables. RESULTS: During the 2 year period 
from 2005 and 2006, 3500 patients representing 12,769,828 CAD patients were 
identiﬁed. A total of 340 CAD patients representing 1,229,496 patients underwent 
CT scan procedure. Observations with missing data were deleted as it constituted less 
than 1% of the total identiﬁed population. Following variables were found signiﬁ-
cantly associated with probability of getting a CT scan: Painlevel, EKG use, Physician 
seen, Physician assistant seen, Race/ethnicity and Mode of arrival. These variables 
do not act in isolation and interactions between them were considered in the analyses 
CONCLUSIONS: The use of CT scan as a diagnostic tool in CAD patients admitted 
in ED depends on a multitude of interdependent factors such as patient characteristics 
deﬁned by painlevel, race/ethnicity, provider characteristics or the type of provider 
seen and type of health service utilized such as ambulance and concurrent EKG use.
PCV132
COST-EFFECTIVENESS OF PERFUSION IMAGING WITH COMPUTED 
TOMOGRAPHY TO IDENTIFY PATIENTS FOR INTRAVENOUS 
THROMBOLYSIS: A HOSPITAL PERSPECTIVE
Jackson DJ1, Earnshaw S2, Farkouh R2, Schwamm LH3
1GE Healthcare, Buckinghamshire, UK, 2RTI Health Solutions, RTP, NC, USA, 3Massachusetts 
General Hospital, Boston, MA, USA
OBJECTIVES: Better selection of ischemic stroke patients for intravenous recombi-
nant tissue plasminogen activator (IV tPA) treatment based on the penumbral hypoth-
esis as seen through magnetic resonance imaging (MRI) by may improve clinical 
outcomes. However given the limited availability of MRIs in hospitals, MRI-based 
methods may not be feasible. We examined the cost-effectiveness of adding perfusion 
imaging with computed tomography (CTP) to usual computed tomography (CT)-
based methods to examine presence and extent of penumbra such that patients can 
be identiﬁed for IV tPA treatment. METHODS: A decision-analytic model was devel-
oped to estimate costs and outcomes associated with selecting patients for IV tPA 
treatment via CTP compared to current usual care of selection based on CT scan and 
patient history from a hospital perspective. The patient population was similar to that 
observed in the IV tPA clinical trials included in a recent meta-analysis. Clinical data 
was derived from published clinical trials. Costs were obtained from standard US 
costing sources and utilities were obtained from published literature. All costs are 
presented in 2009 US dollars. Outcomes included cost per life-year saved and cost per 
quality-adjusted life-year (QALY) gained. Sensitivity analyses were conducted. 
RESULTS: From the hospital perspective, the addition of penumbral-based CTP selec-
tion improved favorable outcome (modiﬁed Rankin Scale ≤1) by 0.59% and reduced 
cost by $42 compared with usual CT-based selection at hospital discharge. Life years 
and QALYs improved which resulted in the addition of penumbral-based CTP selec-
tion in being cost-savings to hospitals. Multivariate sensitivity analysis predicted 
cost-effectiveness (≤$50,000 per QALY) in 89.2% of simulation runs. CONCLU-
SIONS: Given costs and the limited availability of MRI, penumbral-based CTP after 
routine CT is a cost effective alternative for hospitals in selecting ischemic stroke 
patients for IV tPA treatment.
PCV133
THE COST-EFFECTIVENESS OF GENOTYPING CYP2C19 TO GUIDE 
ANTIPLATELET THERAPY SELECTION
Reese ES1, Mullins CD1, Beitelshees AL2, Onukwugha E1
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland, 
Baltimore, Baltimore, MD, USA
OBJECTIVES: The recent re-label of clopidogrel to include information on CYP2C19 
genotype and the approval of a second-generation antiplatelet medication, prasugrel, 
could greatly impact the way antiplatelet therapy is prescribed. This study assesses the 
cost-effectiveness of genotyping patients to guide selection of antiplatelet therapy with 
clopidogrel or prasugrel. METHODS: A decision tree was created using prevalence 
of CYP2C19 metabolism status, cardiovascular events, and bleeding events and costs 
of events as reported in the literature and publically available FDA advisory committee 
documents. In the genotype arm, an individual’s metabolic status determined medica-
tion selection. Effect was deﬁned as the cost per event avoided. Scenario analyses that 
were conducted to determine the robustness of the model included scenario A: clopi-
dogrel use without genotyping and scenario B: prasugrel use without genotyping. 
Number needed to genotype to avoid one cardiovascular or bleeding event from 
occurring was also determined. RESULTS: The probability of being an ultra-rapid or 
extensive metabolizer of CYP2C19 was 73% and the probability of being an inter-
mediate or poor metabolizer was 27%. For the no-genotype arm, the estimated pro-
portions of medication selection used were 70% to receive clopidogrel and 30% to 
receive prasugrel. The model favored the intervention of genotyping patients to deter-
mine antiplatelet therapy (ICER: −$20,049). Both scenario analyses exhibited a domi-
nant strategy of genotyping patients (ICERA: −$21,833 and ICERB: −$15,918). 
Number needed to genotype to avoid one bleeding or cardiovascular event was 26. 
CONCLUSIONS: The cost-effectiveness analysis suggests it is more effective and less 
costly to genotype patients prior to selecting clopidogrel or prasugrel for the patient’s 
antiplatelet therapy.
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OBJECTIVES: Patients who self-discharge against medical advice (AMA) may be at 
higher risk for a hospital readmission if the unauthorized discharge was premature. 
The study objective is to examine the relationship between discharges AMA and 
cardiovascular disease (CVD) hospital readmissions while addressing bias due to 
potential confounding, selection, and hospital-level clustering. METHODS: This 
cross-sectional study uses conﬁdential inpatient hospital discharge data covering the 
years 2000 to 2005. The outcome variables captured readmissions for a CVD-related 
condition following an index CVD-related admission. The covariate of interest was 
an indicator variable for a discharge AMA in the index hospitalization. The relation-
ship between discharges AMA and 7-day, 31-day, 180-day, and 365-day hospital 
readmissions was examined using generalized linear models with adjustments for 
clustering and selection bias. RESULTS: The sample included 443,088 patients, of 
which 22,757 (5.1%) were readmitted to the same hospital. Approximately 1% of 
the patients who were readmitted in the hospital during the study period left AMA 
on the index admission while 0.89% of those who were not readmitted left AMA (p 
= 0.047). The odds of a CVD-related readmission within 7 days, 31 days, 180 days 
and 365 days were 145% (p < 0.001), 55% (p < 0.001), 26% (p < 0.001) and 15% 
(p = 0.0011) higher for patients discharged AMA on index admission compared to 
those who were discharged formally. Results are robust to corrections for observable 
selection bias (via propensity score analysis) and hospital-level clustering. CONCLU-
SIONS: A self-discharge AMA among patients admitted for CVD is predictive of 
CVD-related readmissions and the strength of association increases as the time 
between admissions decreases.
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OBJECTIVES: Future reﬁnement of pharmacotherapy of atrial ﬁbrillation/atrial ﬂutter 
(AF) requires a detailed understanding of how treatments are currently employed in 
clinical practice. METHODS: In this retrospective cohort study, we used the US 
MarketScan® database to identify patients ≥18 years with AF (≥1 AF inpatient or ≥2 
outpatient AF claims) and ≥18 months’ continuous enrollment data between Jan 2003 
and Sept 2007. The ﬁrst qualifying AF diagnosis following 12 months’ enrollment was 
designated the index diagnosis. AF was classiﬁed as newly-diagnosed (ND) or pre-
existing (PRE), based on treatment history in the pre-index period. RESULTS: Of 
184,155 identiﬁed patients (mean age 73 years, 55% men), 64,669 had ND and 
119,486 had PRE AF. Non-pharmacotherapy for AF was undertaken in 11% of 
patients with ND vs 6% of patients with PRE disease, most commonly cardioversion 
(9% vs. 4% of patients, respectively). Across both patient groups, 30% received no 
drug therapy within 30 days of initial AF diagnosis (initial treatment), 17% received 
antiarrhythmics (rhythm-control agents), 51% rate-control agents, 40% anticoagu-
lants, and 5% antiplatelets (aspirin use was not captured). Median duration of uninter-
rupted initial therapy was 210 days for antiarrhythmics and antiplatelets, 228 days 
for anticoagulants and 420 days for rate-control agents. Over the entire post-index 
follow-up period (mean 20 months), ND and PRE AF patients received antiarrhyth-
mics (27% vs 28%), rate-control agents (77% vs 76%), anticoagulants (54% vs. 66%) 
and antiplatelets (14% vs. 10%). Overall, the most commonly used drugs were amio-
darone (15%), β-blockers (56%), calcium channel blockers (23%), cardiac glycosides 
(35%), warfarin (61%) and clopidogrel (11%). CONCLUSIONS: Non-pharmacolog-
ical interventions for AF were relatively uncommon. Almost one-third of AF patients 
in our study remained untreated for the ﬁrst 30 days after diagnosis, which may 
represent under-treatment. Rate-control agents and anticoagulants were used more 
frequently than antiarrhythmics and antiplatelets for treatment of AF.
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OBJECTIVES: Coincident with the increasing focus on comparative effectiveness 
research (CER), a number of organizations have begun to engage in prioritizing 
topics for CER. This paper presents the priority-setting process developed by the 
Center for Medical Technology Policy (CMTP) and its application to the selection 
of cardiac technologies. METHODS: We reviewed criteria and processes used by 
other organizations. We then developed a multi-stage process including, 1) horizon 
scanning; 2) topic nomination; 3) expert solicitation; 4) topic review and selection; 
5) criteria application and discussion by a expert workgroup, and 6) ﬁnal ranking 
of topics for varied research projects. After internally reﬁning a broad list to the 
top ten technologies, we convened an expert workgroup charged with ranking these 
top technologies using prospectively developed criteria. Experts were provided with 
a list of criteria and briefs summarizing clinical, economic, and ethical aspects of 
each technology. RESULTS: Topic nomination produced an initial list of approxi-
mately 40 technologies, which were narrowed to the top ten based on suitability 
for CMTP’s coverage with evidence development (CED) initiatives and guidelines 
